Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

White House Mulls Proposal To Pause FDA's Quality Metrics Initiative

Executive Summary

Trump administration briefing materials show that the pharmaceutical industry's complaints about FDA's quality metrics initiative are getting high-level attention.

Advertisement

Related Content

FDA's Kopcha Presses Ahead On Quality Metrics Despite Industry Pushback
FDA Cites Lupin For Poor Quality Metric Performance
Trump Exec Order On Drug Costs: Seeking To Balance Access, Innovation
Pricing Deregulation: 340B Pharmacy Policy, Medicaid Payment Rules May Be Withdrawn
Trump Administration's Pharma-Friendly Pricing Proposals Prompt Pushback
US FDA And OMB Should ‘Pause’ Billion-Dollar Quality Metrics Program, Industry Groups Say

Topics

Advertisement
UsernamePublicRestriction

Register

PS120941

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel